Literature DB >> 16817012

Genetic and biochemical characterization of 16 acute intermittent porphyria cases with a high prevalence of the R173W mutation.

J To-Figueras1, C Badenas, C Carrera, C Muñoz, M Milá, M Lecha, C Herrero.   

Abstract

Acute intermittent porphyria (AIP) is a metabolic disease with a variable prevalence among different countries. In some areas of southern Europe it remains to be fully evaluated. We undertook a genetic and biochemical study of 16 unrelated Spanish AIP patients and relatives. The genetic analyses showed they harboured the following mutations in the porphobilinogen deaminase gene: R173W, G111R, L278P, L238P, R116W, R26C, 340insT, 730delCT, 691del30bp, and IVS14+1g>a. The mutation R173W was found in 6 patients (37.5%), including the only patients of our series with >3 recurrent porphyria attacks. While in clinical remission, all AIP patients exhibited sustained increased excretion of porphyrins and precursors. PBG excretion showed a high between-subject variation and was not related to erythrocyte PBG deaminase activity. The study of family members allowed the identification of 22 asymptomatic AIP carriers. These included 8 persons harbouring the R173W mutation belonging to four different families. Six of these latent AIP subjects showed increased PBG elimination, and in two the urinary levels were >10-fold the normal limit. These results reinforce the hypothesis that the R173W mutation may have a high biochemical and clinical penetrance among AIP patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817012     DOI: 10.1007/s10545-006-0344-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  37 in total

1.  Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation.

Authors:  A De Siervi; M V Rossetti; V E Parera; K H Astrin; G I Aizencang; I A Glass; A M Batlle; R J Desnick
Journal:  Am J Med Genet       Date:  1999-10-08

Review 2.  Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias.

Authors:  S Thunell; P Harper; A Brock; N E Petersen
Journal:  Scand J Clin Lab Invest       Date:  2000-11       Impact factor: 1.713

3.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Frequency of low erythrocyte porphobilinogen deaminase activity in Finland.

Authors:  P Mustajoki; R Kauppinen; L Lannfelt; L Lilius; J Koistinen
Journal:  J Intern Med       Date:  1992-04       Impact factor: 8.989

5.  Investigations on the formation of urinary coproporphyrin isomers I-IV in 5-aminolevulinic acid dehydratase deficiency porphyria, acute lead intoxication and after oral 5-aminolevulinic acid loading.

Authors:  K Jacob; E Egeler; U Gross; M O Doss
Journal:  Clin Biochem       Date:  1999-03       Impact factor: 3.281

6.  Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias.

Authors:  C K Lim; T J Peters
Journal:  Clin Chim Acta       Date:  1984-05-16       Impact factor: 3.786

7.  A retrospective study of a patient with homozygous form of acute intermittent porphyria.

Authors:  G J Beukeveld; B G Wolthers; Y Nordmann; J C Deybach; B Grandchamp; S K Wadman
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

8.  Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.

Authors:  R Kauppinen; P Mustajoki
Journal:  Medicine (Baltimore)       Date:  1992-01       Impact factor: 1.889

9.  High prevalence of a point mutation in the porphobilinogen deaminase gene in Dutch patients with acute intermittent porphyria.

Authors:  X F Gu; F de Rooij; J S Lee; K Te Velde; J C Deybach; Y Nordmann; B Grandchamp
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

10.  Novel HMBS founder mutation and significant intronic polymorphism in Spanish patients with acute intermittent porphyria.

Authors:  E Guillén-Navarro; P Carbonell; G Glover; M Sánchez-Solís; A Fernández-Barreiro
Journal:  Ann Hum Genet       Date:  2004-09       Impact factor: 1.670

View more
  6 in total

1.  Seven Novel Mutations in Bulgarian Patients with Acute Hepatic Porphyrias (AHP).

Authors:  Sonya Dragneva; Monika Szyszka-Niagolov; Aneta Ivanova; Lyudmila Mateva; Rumiko Izumi; Yoko Aoki; Yoichi Matsubara
Journal:  JIMD Rep       Date:  2014-07-06

2.  Systematically Analyzing the Pathogenic Variations for Acute Intermittent Porphyria.

Authors:  Yibao Fu; Jinmeng Jia; Lishu Yue; Ruiying Yang; Yongli Guo; Xin Ni; Tieliu Shi
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

Review 3.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

4.  Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study.

Authors:  Oscar J Pozo; Josep Marcos; Andreu Fabregat; Rosa Ventura; Gregori Casals; Paula Aguilera; Jordi Segura; Jordi To-Figueras
Journal:  Orphanet J Rare Dis       Date:  2014-04-16       Impact factor: 4.123

5.  Many pitfalls in diagnosis of acute intermittent porphyria: a case report.

Authors:  N L R Indika; T Kesavan; H W Dilanthi; K L S P K M Jayasena; N D P D Chandrasiri; I N Jayasinghe; U M T Piumika; D M Vidanapathirana; K D A V Gunarathne; M Dissanayake; E Jasinge; W Kodikara Arachchi; D Doheny; R J Desnick
Journal:  BMC Res Notes       Date:  2018-08-02

6.  Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics.

Authors:  Alex Gomez-Gomez; Paula Aguilera; Klaus Langohr; Gregori Casals; Cristina Pavon; Josep Marcos; Jordi To-Figueras; Oscar J Pozo
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.